TAE Life Sciences
  • OUR COMPANY
    • ABOUT US
    • LEADERSHIP TEAM
    • BOARD OF DIRECTORS
    • ADVISORS
    • CAREERS
  • ABOUT BNCT
    • HISTORY
    • HOW IT WORKS
    • BENEFITS OF BNCT
  • OUR TECHNOLOGIES
    • ALPHABEAM NEUTRON SYSTEM
    • TARGETED BORON DRUGS
  • NEWS
    • NEWS
    • EVENTS
  • CONTACT US
  • NEW EBOOK
  • OUR COMPANY
    • ABOUT US
    • LEADERSHIP TEAM
    • BOARD OF DIRECTORS
    • ADVISORS
    • CAREERS
  • ABOUT BNCT
    • HISTORY
    • HOW IT WORKS
    • BENEFITS OF BNCT
  • OUR TECHNOLOGIES
    • ALPHABEAM NEUTRON SYSTEM
    • TARGETED BORON DRUGS
  • NEWS
    • NEWS
    • EVENTS
  • CONTACT US
  • NEW EBOOK

Press Releases

logo_businesswire
February 12, 2022

TAE Life Sciences to Sponsor Industry Expert Theater “New Era in Biologically-Targeted Radiation Therapy” at 2021 ASTRO Annual Meeting

10/2021 | Business Wire

The session, “New Era in Biologically-Targeted Radiation Therapy: Clinical Application and Technical Advancement in Boron Neutron Capture Therapy” will feature presentations by Timothy Malouff, M.D., Mayo Clinic, Ester Orlandi, M.D., National Center of Oncological Hadrontherapy (CNAO) and Kendall Morrison, Ph.D., Chief Scientific Officer, TAE Life Sciences. They will discuss the clinical application and technical advancements in BNCT for the treatment of invasive, recurrent and difficult to treat cancers.

logo_businesswire
February 12, 2022

TAE Life Sciences Partners with BEC to Incorporate Specialized Robotic Patient Positioning System in its Alphabeam™ System for High-Precision Boron Neutron Capture Therapy

9/2021 | Business Wire

During BNCT, it is essential that the patient is positioned accurately in relation to the radiation beam and that the radiation therapist has the ability to adjust the patient’s position throughout the whole treatment session. BEC will be developing a unique chair setup that will allow for flexible patient treatment in a seated position in addition to the traditional treatment couch configuration. Exclusively designed for TLS’ Alphabeam™ Neutron System, the chair is optimal for treating specific types of head and neck cancers.

logo_businesswire
February 12, 2022

TAE Life Sciences Announces Installation of First Accelerator-based Neutron Beam System for Biologically Targeted Radiation Therapy at Xiamen Humanity Hospital in China

9/2021 | Business Wire

TLS’ Neutron Beam System enables a new treatment modality for patients diagnosed with the most aggressive and recurrent cancers such as gliomas, head and neck tumors, and melanomas, by delivering more precise, targeted radiation to cancer cells while sparing damage to surrounding healthy tissue. This technique holds promise in treating patients with cancer for whom other treatment options have been exhausted or are unavailable.

logo_businesswire
February 12, 2022

TAE Life Sciences Identifies Proprietary Drug Candidates to Support Boron Neutron Capture Therapy (BNCT)

2021 | Business Wire

“TLS is the only company developing comprehensive, in-house target drugs as well as a neutron technology system called Alphabeam™ to enable the next-generation in biologically targeted radiation therapy. Today’s news brings us closer to our goal of providing new hope to patients with the most difficult to treat cancers,” said Bruce Bauer, PhD, CEO of TAE Life Sciences. “Historically, brain, head and neck, and melanoma cancers have been treated with BNCT and studies have shown improvements in survival compared to other cancer therapies. New boron drugs expand the potential to treat other indications including breast, lung and liver cancers.”

TLS-News5_sm
October 27, 2020

TAE Life Sciences and CNAO (National Center of Oncological Hadrontherapy) Announce a Research and Clinical Collaboration for the Implementation of a New Facility with Boron Neutron Capture Therapy System in Italy

2020 | Business Wire

TAE Life Sciences (TLS), a biologically-targeted radiation therapy company developing a breakthrough, accelerator-based boron neutron capture therapy (BNCT) system, today announced that it has entered into an agreement with National Center of Oncological Hadrontherapy (CNAO) to provide its Alphabeam™ Neutron System for the treatment of invasive, recurrent and difficult to treat cancers.

2020_summer_private_company
August 7, 2020

TAE Life Sciences to Present at Solebury Trout Summer 2020 Private Company Showcase

2020 | Business Wire

TAE Life Sciences (TLS) is a privately-held biotechnology company committed to developing a new biologically-targeted radiation therapy based on Boron Neutron Capture Therapy (BNCT). TLS is developing the next generation targeted boron drugs and low-energy accelerator-based neutron source – optimized for an in-hospital BNCT program that can one day treat patients with the most aggressive and recurrent cancers.

TLS-and-RaySearch
June 2, 2020

TAE Life Sciences Secures $30M in Initial B Round Phase to Accelerate Development of Unique Boron Delivery Drugs for Novel Cancer Treatment

2020 | Market Watch

TAE Life Sciences (TLS), a biological-targeting radiation therapy company developing next-generation boron neutron capture therapy solutions (BNCT), announced the launch of an innovative in-house boron delivery drug development program supported by an influx of $30M in funding. The initial phase of the B-round funds comes from a consortium of investors including ARTIS Ventures, who led the company's initial funding in 2018.

logo_prn_cision
September 15, 2019

TAE Life Sciences Announces Scientific Advisory Board to Advance Cancer Research in Boron-Neutron Capture Therapy

2019 | Cision PR Newswire | Read Now

BNCT is unique in its ability to deliver targeted therapy to destroy cancer cells with biological precision and has shown compelling results in treating some of the most challenging cancers, including brain, head and neck tumors and melanomas. BNCT uses the benign boron-10 isotope in a targeting drug that naturally embeds within fast-growing cancer cells, which then receive an intense, highly localized dose of radiation activated by a low-energy neutron beam.

BNCT-accelerator
May 17, 2019

Boron Neutron Capture Therapy Progresses Towards Clinical Cancer Treatments

2019 | Physics World | Read Now

The main obstacle to BNCT has been that a nuclear reactor was required to generate the neutron beams needed for treatments. To overcome this problem, TAE Life Sciences is developing an accelerator-based neutron source. “We have created a low-energy neutron beam source that is reliable, compact and can be installed in a hospital facility,” says Bruce Bauer, CEO of TAE Life Sciences. “This changes the game on BNCT.”

Newer
12
Older

Sign up for our latest news and information

* indicates required




TAE Life Sciences, 19631 Pauling, Foothill Ranch, CA 92610

* The TAE Life Sciences device and drugs are in development and not available for sale or commercial use

Copyright ©2020 TAE Life Sciences. All Rights Reserved.